Redefining Muscle Aging in Asia: Customizing Sarcopenia Interventions for Better Health
Sarcopenia, the age-related decline in muscle mass and function, poses significant health risks for older adults, including increased fall risk and mortality. Recent research focuses on its prevalence in Asian populations, highlighting the need for region-specific diagnostic criteria due to unique muscle mass patterns, especially in women. This insight challenges the universal applicability of existing sarcopenia guidelines and calls for tailored approaches in Asia.
In response, interventions combining resistance exercise with dietary adjustments are recommended, emphasizing protein intake to sustain muscle health. Pharmaceutical advancements are also noteworthy, with numerous drugs targeting muscle growth and preservation in clinical trials, reflecting a dynamic field keen on innovative solutions.
The study advocates for integrating sarcopenia management into broader chronic disease care, emphasizing personalized medicine's role in enhancing longevity. This approach underscores the complexity of aging and the potential of targeted interventions to improve life quality in older populations.
Article Information
Sarcopenia in the era of precision health: Toward personalized interventions for healthy longevity
Pubished in J Chin Med Assoc. Liang-Kung Chen et al.
Abstract
Sarcopenia, characterized by the progressive loss of skeletal muscle mass and function, significantly impacts health outcomes in older adults. This review explores the evolving landscape of sarcopenia research, with a particular focus on its unique characteristics in Asian populations and emerging pharmaceutical interventions. Recent studies have revealed distinct patterns of muscle mass decline in Asian adults, particularly in women, challenging the universal application of global sarcopenia diagnostic criteria. The Asian Working Group for Sarcopenia has proposed region-specific diagnostic criteria, acknowledging these ethnic variations. Prevalence estimates of sarcopenia vary widely, ranging from 10% to 40% in community-dwelling older adults. For specific chronic conditions, the prevalence of sarcopenia is notably higher, reaching 35% for cardiovascular diseases and 24.5% for chronic kidney disease. Sarcopenia is strongly associated with various chronic conditions, increasing the risk of falls by 1.5 to 3 times and significantly increasing mortality risk by 29% to 51%. Current management strategies primarily involve resistance exercise and nutritional interventions, with a recommended daily protein intake of at least 1.2 g/kg to maintain muscle health. Pharmaceutical development has gained significant momentum, with over 20 compounds in various stages of clinical trials. These include myostatin inhibitors, selective androgen receptor modulators, ghrelin receptor agonists, mesenchymal stem cell therapy, and follistatin gene therapy. However, the unique dietary patterns, cultural contexts, and potentially distinct drug responses in Asian populations necessitate tailored interventions and Asia-specific clinical trials. Future directions include refining Asian-specific diagnostic criteria, conducting large-scale epidemiological studies across multiple Asian countries, developing culturally appropriate interventions, integrating sarcopenia management into chronic disease care, and advancing pharmaceutical research with a focus on Asian populations. In conclusion, sarcopenia emerges as a critical nexus in the aging process, intricately linked with multiple organ systems and chronic conditions, underscoring the imperative for its recognition as a cornerstone in person-centered care and the holistic management of age-related health challenges.
Bring preventive care to your clinic
© Longevity Artificial Intelligence. All rights reserved.